Fact sheet: International Biotechnology IT

Rated Fund Information
Rated Funds Group
?Money Observer has arranged all its Rated Funds into easy to understand Rated Fund Groups, comprising funds and investment trusts.
SPECIALIST
Sector
IT Biotechnology & Healthcare
Fund type
Investment Trust
Primary aim
No data available.
Why Money Observer Rates International Biotechnology IT

Rated Fund 2017-2018. Provides diverse exposure to biotechnology companies

International Biotechnology is managed by a three-strong team at SV Life Sciences ヨ Carl Harald Janson, Kate Bingham and Ailsa Craig, whose backgrounds combine medical and/or scientific training, financial and commercial experience. This experience enables them to assess potential investment opportunities and consider which companies are the most likely to succeed, from a position of technical expertise and experience. The trust invests in unquoted, usually earlier stage companies, as well as quoted equities. This broad spectrum of investments provides diversification while still giving exposure to potentially exciting returns.The managers invest in companies with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. They specialise in identifying the successful innovative drugs and medical devices that will serve unmet medical needs and which are in complex disease areas such as diabetes and cancer, as well as the most credible treatments for 'orphan' diseases where the number of patients may be fewer but the path to approval may be smoother with less competition.The types of company they select provide investors with exposure to businesses at different stages of their development, from early stage innovation, across regulatory hurdles, through to regulatory approval and revenue generation.The trust predominantly aims to provide long-term capital growth but in 2016 introduced a dividend equivalent to 4 per cent of net asset value, paid half-yearly out of capital reserves. Its shares have traded on a discount of as wide as 23 per cent over the past three years, but at the end of 2017 roughly reflected the value of underlying assets.<\p>

3 Year Performance
Fund Performance6.7%
Average of Rated Funds Group41.4%
Sector Performance9.9%
Fund information
Fund name
International Biotechnology Trust
Fund manager company
SV Health Managers
Fund type
Investment Trust
Fund managers
  • Carl Harald Jansonsince 02/09/2013
  • Kate Binghamsince 01/11/2000
  • Ailsa Craigsince 01/04/2006
Accolades
Fund objective
The investment objective of International Biotechnology Trust plc (the “Company”) is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies that are either quoted or unquoted and possess the potential for high growth. The Company invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or commercialization of a product, device or enabling technology.
Benchmark
  • NASDAQ Biotechnology
Investment style
No data available.
Investment method
No data available.
Quick stats
1 Year return
-0%
1 Year rank in sector
3/6
Sector
IT Biotechnology & Healthcare
Yield
4.6%
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.3%
Fund size
£206m
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
186
Mid price
549
NAV
?Net asset value. The NAV per share may be higher or lower than the share price, which in turn is trading at either a discount or a premium to NAV.
576.95
Discount/Premium
?When the market price of an investment trust’s shares is less than the net asset value (NAV) per share then it is trading at a discount to NAV. A trust’s shares are on a premium when they trade at a higher price than the NAV.
-4.84
Gearing
?Investment trusts have the ability to borrow money which they invest with the aim of generating a higher return than the cost of the loan. An ungeared trust has a figure of 100. A figure of 110 would represent a trust with 10% gearing.
100
Top in this sector
Fund name1 Year
Syncona Limited36.7%
Wldwide Hlthcare Tst PLC7.9%
Intl Biotechnology Trust-0%
The Biotech Growth Trust PLC-3.2%
BB HlthcareTstPlcRedOrd1P-3.7%
...more in IT Biotechnology & Healthcare

Performance snapshot

Holdings snapshot

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-3.7%-9%-10.4%-0%6.7%141.3%
Sector-4.4%-9.5%-9.1%1.1%9.9%103.7%
Rank within sector4 / 63 / 64 / 63 / 64 / 52 / 5
Quartile3rd2nd3rd2nd4th2nd
Calendar performance
 YTD - 20182017201620152014
Fund-10.2%18.3%1.6%22.2%48.2%
Sector-8.2%15.6%6.2%12.7%39.3%
Rank within sector4 / 63 / 64 / 51 / 51 / 5
Quartile3rd2nd4th1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-0.95
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.32
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
-0
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
24.33
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
8.74
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.09
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.94
Price movement
52 week high644.25
52 week low522
Current bid price546
Current offer price552
Current mid price549
Region
1North America89%
2Europe11%
Industry sector
No data available.
Asset type
1North American Equities89%
2European Equities11%
Individual holdings
1ARRAY BIOPHARMA INC4.7%
2BIOGEN INC4.2%
3CELGENE CORP4.2%
4NEUROCRINE BIOSCIENCES INC4.2%
5GENMAB AS3.7%
6REGENERON PHARMACEUTICALS INC3.7%
7SAGE GOLD INC3.6%
8VERTEX PHARMACEUTICALS INC3.6%
9GILEAD INC3.3%
Management
Fund manager group
SV Life Sciences
Fund manager company
SV Health Managers
Fund type
Investment Trust
Fund objective
The investment objective of International Biotechnology Trust plc (the “Company”) is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies that are either quoted or unquoted and possess the potential for high growth. The Company invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or commercialization of a product, device or enabling technology.
Benchmark
  • NASDAQ Biotechnology
Investment style
No data available.
Investment method
No data available.
Fund managers
NameSinceBiography
Carl Harald Janson02/09/2013Carl Harald joined SV Health in September 2013 as lead IBT Investment Manager for the quoted portfolio. Carl Harald qualified as a Medical Doctor and completed a PhD at the Karolinska Institutet, and is a Certified Financial Analyst from the Stockholm School of Economics. Prior to joining SV Health Carl Harald worked as Director preclinical research for Astra Arcus AB, Senior Financial Analyst for Hagströmer and Qviberg Fondkommission AB and Danske Securites, Fund Manager at Carnegie Investment Bank, and Investment Manager at Karolinska Development AB. Carl Harald has also served as CEO and Member of the Board of several Scandinavian biotech companies.
Kate Bingham01/11/2000Kate joined SV Health in 1991 and is one of the firm’s Managing Partners. Kate has been responsible for a number of successful venture capital investments in biotechnology companies and has served on the boards of a number of companies in the United States and Europe. Prior to joining SV Health, Kate worked for Vertex, a biotechnology company and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.
Ailsa Craig01/04/2006Ailsa joined SV Health in November 2006 as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team. Previously, Ailsa worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks. Prior to this, Ailsa worked for Insight Investment / Rothschild Asset Management (merged 2003) as the Global Healthcare Analyst. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007.
Compliance
AIC Member
Domicile
No data available.
Fund for sale in
United Kingdom
International Biotechnology Trust
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price581.19
CurrencyGBX
Price updated19/04/2018
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeNJHF
International Biotechnology Trust NAV
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price581.19
CurrencyGBX
Price updated19/04/2018
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeUM76
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.